Skip to content
TrialScanner

NCT05358821

28-Day Study of SAGE-718 on Functioning Capacity in Participants With Huntington's Disease

Phase 2CompletedSUPNLead

Registry record

Lead sponsor
Supernus Pharmaceuticals, Inc.
Conditions
Huntington Disease
Primary completion
Feb 29, 2024Actual
Completion
Locked
Start
Locked
Enrollment
Locked
Interventions
Locked
Study type
Locked
Results on the registry
Locked
Record last updated
Locked

Open NCT05358821 on ClinicalTrials.gov

Enrollment, interventions, the start and completion dates and the change history are locked on 1 row here. Included with TrialScanner ($9.99 a month) and Signal8 Pro.

Unlock with TrialScanner

Recorded changes

0 changes recorded for this trial. The history, with each previous value, is part of TrialScanner.

Tracking since Nov 12, 2026. Changes before that date are not known to TrialScanner.

    NCT05358821: 28-Day Study of SAGE-718 on... | TrialScanner